Saturday 17 October 2026
Export AURA’s income statement to Excel — free account
Aura Biosciences, Inc.
AURA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 2.13% and free cash flow fell 56.3%, each against the same quarter a year earlier.
6.10
0.24
−3.79%
Follow AURA
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 13.50 | 9.43 | 5.99 | 6.63 | 4.35 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 26.16 | 24.83 | 13.50 | 12.38 | 8.60 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 42 | 52 | 72 | 89 | 109 | 113 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | (24) | (22) | (35) | (59) | (76) | (87) | (106) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (24) | (22) | (35) | (59) | (76) | (87) | (106) | |||||
| Depreciation | — | — | — | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (1.03) | (60.51) | (8.95) | (1.96) | (1.93) | (1.75) | (1.76) | |||||
| Cash flow | — | — | — | (0.71) | (66.27) | (6.28) | (1.82) | (1.61) | (1.61) | (1.40) | |||||
| Capex | — | — | — | 0.00 | (2.10) | (0.41) | (0.04) | (0.02) | (0.03) | (0.01) | |||||
| Free cash flow | — | — | — | (0.71) | (68.37) | (6.69) | (1.86) | (1.63) | (1.63) | (1.41) | |||||
| Book value | — | — | — | 1.05 | (296.22) | 29.52 | 6.53 | 5.70 | 3.06 | 2.27 | |||||
| Shares, m | — | — | — | 29 | 0 | 5 | 30 | 40 | 50 | 60 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (21) | (24) | (32) | (55) | (64) | (80) | (85) | ||||
| Capex | — | — | — | (2) | (1) | (2) | (1) | (1) | (1) | 0 | |||||
| Free cash flow | — | — | — | (21) | (25) | (35) | (56) | (65) | (81) | (85) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 27 | 16 | 146 | 186 | 219 | 146 | 131 | ||||
| Total debt | — | — | — | 0 | 0 | 1 | 21 | — | — | — | |||||
| Net debt | — | — | — | (32) | (17) | (149) | (189) | (226) | (151) | (144) | |||||
| Shareholders’ equity | — | — | — | 31 | (109) | 152 | 196 | 226 | 152 | 137 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (163.16) | (101.87) | (50.72) | (30.61) | (31.90) | (39.73) | (60.35) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | (682.29) | (558.12) | 0.00 | (6,857.59) | 0.00 | |||||
| ROE | — | — | — | 30.83 | 30.73 | (211.88) | (33.78) | (36.26) | (46.01) | (73.52) | |||||
Negative figures in brackets.
Charts ten years each
Aura Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ANNX Annexon, Inc. | $682.5M | — (loss-making) | — | — | n/m | −26.41% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MDXG MiMedx Group, Inc | $682.2M | 111× | — (loss-making) | −34.73% (below 0%: shrinking) | n/m | −174.83% (below 0%: shrinking) | 68.96% | (28.69%) | Compare |
| CADL Candel Therapeutics, Inc. | $681.8M | — (loss-making) | — (loss-making) | 0.00% | n/m | −93.35% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PHAR Pharming Group N.V. Sponsored ADR | $681.6M | 62.4× | — (loss-making) | −3.22% (below 0%: shrinking) | −57.14% (below 0%: shrinking) | −183.87% (below 0%: shrinking) | 83.92% | 1.44% | Compare |
| GYRE Gyre Therapeutics, Inc. | $678.6M | — (loss-making) | — (loss-making) | −2.12% (below 0%: shrinking) | n/m | −130.45% (below 0%: shrinking) | 92.41% | (49.35%) | Compare |
| AURA Aura Biosciences, Inc. | $657.5M | — (loss-making) | — | — | n/m | −56.26% (below 0%: shrinking) | 0.00% | 0.00% | |
| DSGN Design Therapeutics, Inc. | $655.9M | — (loss-making) | — (loss-making) | — | n/m | −7.00% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PRME Prime Medicine, Inc. | $654.8M | — (loss-making) | — (loss-making) | +3.50% (above 0%: growing) | n/m | +4.40% (above 0%: growing) | 100.00% | (3,750.87%) | Compare |
| AVTX Avalo Therapeutics, Inc. | $644.1M | — (loss-making) | — (loss-making) | −70.14% (below 0%: shrinking) | n/m | +75.70% (above 0%: growing) | 55.73% | 0.00% | Compare |
| Median of peers | $680.1M | — | — | −2.67% | — | −59.88% | 62.35% | 0.00% |
Aura Biosciences, Inc. (AURA) key facts
- Aura Biosciences, Inc. (AURA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, AURA traded at $6.10, a market capitalization of $657.5 million.
- Return on equity was −73.5% and debt-to-equity 0.00.
Aura Biosciences, Inc. (AURA) Latest News
No news at this impact. Lower the threshold for more.